Carlos H. Rios Martinez* and Armando A. Durant-Archibold* Pages 330 - 342 ( 13 )
Leishmaniasis is a neglected tropical disease caused by around 20 species of obligate intramacrophage protozoa of the genus Leishmania. This disease is an important cause of morbidity and mortality that primarily impacts the poorest populations living in tropical and sub-tropical regions of the world, but has become of concern in some developed countries. The resistance of leishmanial parasites to the drugs available and their undesirable side effects have prompted the discovery of new synthetic compounds with potent antileishmanial activity and fewer side effects that can serve as new therapeutic agents. In this article, we make a comprehensive review of the most recent advances of synthetic compounds with antileishmanial activity (from 2015 to the early 2017). Furthermore, we covered the structure- activity relationship studies that allow for optimization and selection of the most promising drugs, and the biochemical mechanisms that explain the antileishmanial activities observed.
Antileishmanial agents, chemotherapy, leishmaniasis, Leishmania, neglected tropical diseases, synthetic compound.
Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia (INDICASAT AIP), Panama City, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia (INDICASAT AIP), Panama City